Shares of Hyperion Therapeutics soared nearly 20% today after receiving notice that the Food and Drug Administration would not meets its January PDUFA date for Ravicti. However, the reasons for the UCD drug's delay have the bulls out in full force. Watch as Motley Fool health care analyst David Williamson explains what has investors so excited and what it means for Hyperion.
Jan 16, 2013 at 4:12PM
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings... Follow @motleydavid
Motley Fool Returns
Stock Advisor S&P 500
Stock Advisor launched in February of 2002. Returns as of 02/24/2020.Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return